Butorphanol (Tartrate)

Also known as: Butorfanor tartarate, Butofanoli Tartaras

Drug #828

Butorphanol (Tartrate) is opioid analgesic. Butorphanol (Tartrate) is used to relieve the pain. It has some narcotic activity. Butorphanol (Tartrate) is used to relieve pain of surgical procedures and labor and to enhance the effects of anesthesia. its long term use can produce dependence, In case of overdose its antidote is raloxone.

← Previous drug Next drug →

Primary Characteristics

Butorphanol (Tartrate) is also known as Butorfanor tartarate, Butofanoli Tartaras.

It is of Synthetic origin and belongs to Morphine-Opioid.

It belongs to OPIATE agonist pharmacological group on the basis of mechanism of action. It is also classified under Analgesics and Anti-inflammatory Agents .

Molecular Weight: 477.5 · Solubility in Water: sparingly soluble · Solubility in Alcohol: insoluble · Non-proprietary name: Butorphanol (Tartrate).

Molecular structure of Butorphanol (Tartrate)

Pharmacokinetics

Absorption: Butorphanol (Tartrate) has an oral bioavailability is 70% (±20%).

Distribution: Butorphanol (Tartrate) has a volume of distribution is 12l/kg. plasma protein binding is 80%.

Elimination: it is metabolised via Hepatic, plasma half-life is 4.5 hrs, renal excretion is 1.05%.

Indications

Butorphanol (Tartrate) is primarily indicated in conditions like Headache, Labor pains, Migraine, Pre-anaesthetic medication.

Butorphanol (Tartrate) is also indicated for secondary conditions like Dental surgery.

Contraindications

Butorphanol (Tartrate) is contraindicated in conditions like Hypersensitivity to the drug.

Dosage

Butorphanol (Tartrate)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
2.5 mg	2.5 mg	Every 4h	IM
1 mg/spray/nostril	1 mg/spray/nostril	—	Intra Nasal Spray	60-90 minutes if necessory.An initial dose of 2 mg may be given in severe pain but should not be repeated 3-9 hours.
2 mg/spray/nostril	2 mg/spray/nostril	Every 4h	Intra Nasal Spray	In severe pain
1.25 mg	1.25 mg	Every 4h	IV
Paediatric Dosage (20kg)
0 – 0	—	—	—	Not Recommended in this Age Group
Neonatal Dosage (3kg)
0 – 0	—	—		Not recommended in this age group

Drug Interactions

Unknown5 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

The signs and symptoms that are produced after acute overdosage of Butorphanol (Tartrate) are Coma, Respiratory depression, Respiratory depression, Pinpoint pupils, Respiratory depression.

Butorphanol (Tartrate) is known to cause more or less tolerable side effects which are usually transient. These include Anxiety, Asthenia , Confusion, dizziness, Dry mouth, Dyspnea, Headache, Insomnia, Lethargy, Nasal congestion , Nasal irritation, Nausea, Palpitation, Stomachache , Tinnitus, Tremor, Vomiting , Xerostomia .

Warnings / Precautions

Butorphanol should be used with caution and in low doses in patients with respiratory depression, pulmonary disease, cardiac, renal or liver impairment, in GI disease including GI obstruction, ulcerative colitis or pre-existing constipation. Abrupt discontinuation or prolonged therapy can result in withdrawal symptoms.Although Cardio vascular Effects may be lessthan pentrazoline,butophanol should be generally avoided in M.I

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inj

1 mg/ml

Storage Conditions

Butorphanol (Tartrate) should be stored Aerosol, Inj.

Drug Classification

1.2.2 — Opioid analgesics

Manufacturers

Manufacturers of Butorphanol (Tartrate) in Pakistan:

GSK Siza